These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 36240432)

  • 21. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB
    Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
    Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.
    Mok T; Nakagawa K; Park K; Ohe Y; Girard N; Kim HR; Wu YL; Gainor J; Lee SH; Chiu CH; Kim SW; Yang CT; Wu CL; Wu L; Lin MC; Samol J; Ichikado K; Wang M; Zhang X; Sylvester J; Li S; Forslund A; Yang JC
    J Clin Oncol; 2024 Apr; 42(11):1252-1264. PubMed ID: 38252907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
    Zhu CM; Lian XY; Zhang HY; Bai L; Yun WJ; Zhao RH; Li QS
    J Cancer Res Ther; 2021 Jul; 17(3):664-670. PubMed ID: 34269297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
    Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
    Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell 
Lung Cancer Patients with Acquired EGFR T790M Mutation].
    Gu Y; Tian X; Wang R; Li X; Qian K; Li Y; Nong J
    Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):843-851. PubMed ID: 36617470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
    Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
    Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
    J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis.
    Zhang H; Chen J; Liu T; Dang J; Li G
    PLoS One; 2019; 14(10):e0223530. PubMed ID: 31581247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis.
    Xu C; Zhou Q; Wu YL
    J Hematol Oncol; 2012 Oct; 5():62. PubMed ID: 23050865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
    Lamb YN
    Target Oncol; 2021 Sep; 16(5):687-695. PubMed ID: 34564820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis.
    Liu J; Li X; Shao Y; Guo X; He J
    Medicine (Baltimore); 2020 Aug; 99(34):e21826. PubMed ID: 32846826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of osimertinib in EGFR-mutated non-small cell lung cancer.
    Mezquita L; Varga A; Planchard D
    Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
    Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
    Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.